The Board recognises the importance of sound corporate governance whilst taking into account the size and nature of the Company. As the Company grows, the intention of the Board is that the Company should develop policies and procedures which reflect the Principles of Good Governance and Code of Best Practice, as published by the Committee on Corporate Governance (commonly known as the “Combined Code”) and which are appropriate for a company of its size. The Board will take such measures, as far as is practicable, to comply with the Combined Code. The Directors have established an audit committee and a remuneration committee.
It is intended that the audit committee will meet at least twice per annum and will be responsible for ensuring the integrity of the financial information reported to the shareholders and the systems of internal controls and will determine the terms of engagement of the Company’s auditors. This committee provides an opportunity for reporting by the Company’s auditors. Gerry Desler and George Morris are members of the Audit Committee.
The committee is made up of Oliver De-Giorgio Miller and Kevin Alexander. It is intended that the remuneration committee will meet at least twice per annum to determine and agree with the Board the framework or broad policy for the remuneration of any executive directors of the Company and such other members of any future executive management as it is designed to consider. The objective of this committee is to attract, retain and motivate executives capable of delivering the Company’s objectives.
The Nominations Committee is a sub-committee of the whole Board. The Committee meets as required to select suitable candidates for both executive and non-executive appointments to the Board.
UK City Code on Takeovers and Mergers
Valirx is subject to the UK City Code on Takeovers and Mergers.
Valirx is not required to comply with the UK Corporate Governance Code (the ‘Code’) and does not voluntarily apply the full requirements of the Code. However, our governance arrangements do meet many of the requirements of the Code which the directors’ deem most relevant to an AIM listed company having consideration to the size, nature and scope of the company and group’s activities. These arrangements are fully disclosed in the Corporate Governance section of our 2013 Annual Report and Accounts which can be viewed in the Annual Reports section of this website.
The Bribery Act 2010
ValiRx plc prohibits any inducement which may result in a personal gain or advantage to the recipient or any person or body associated with them, and which is intended to influence them to take action which may not be solely in the interests of ValiRx plc or of the person or body employing them or whom they represent.
The information above was last updated on 23 May 2016.